This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Invitae Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Invitae hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-3,542.9%

Rückkaufsrendite

Gesamte Aktionärsrendite	-3,542.9%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von 0JDB in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von 0JDB gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Invitae Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von 0JDB im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (0JDB)	n/a
Untere 25 % des Marktes (GB)	2.1%
Markt Top 25 % (GB)	5.8%
Branchendurchschnitt (Healthcare)	2.2%
Analystenprognose (0JDB) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von 0JDB im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von 0JDB im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von 0JDB, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da 0JDB keine Ausschüttungen gemeldet hat.

This company is no longer active

Invitae Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Invitae Corporation Filed for Bankruptcy

Motion for Joint Administration Filed by Invitae Corporation

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$3.42 loss per share (vs US$1.27 loss in 3Q 2022)

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.78 loss per share (vs US$10.87 loss in 2Q 2022)

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Corporation Announces Executive Changes

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$13.18 loss per share (vs US$1.80 loss in FY 2021)

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Director recently sold US$115k worth of stock

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases

Third quarter 2022 earnings released: US$1.27 loss per share (vs US$0.91 loss in 3Q 2021)

Invitae Corporation Reiterates Earnings Guidance for the Year 2022

Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022

Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy

Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022

Invitae Corporation Reiterates Revenue Guidance for the Year 2022

Invitae Corporation to Report Q2, 2022 Results on Aug 09, 2022

Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow

Invitae Corporation Announces Executive Leadership and Board Changes

Chief Operating Officer recently sold US$108k worth of stock

Invitae Corporation Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.56 loss in 1Q 2021)

Invitae Corporation, Annual General Meeting, Jun 06, 2022

Invitae Corporation, Annual General Meeting, Jun 06, 2022

Invitae Corporation to Report Q1, 2022 Results on May 03, 2022

Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders

Invitae Announces the Launch of Invitae Digital Health

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Invitae Corporation Provides Revenue Guidance for 2022

Invitae Corporation to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.91 loss per share (vs US$0.78 loss in 3Q 2020)

Invitae Corporation (NYSE:NVTA) entered into definitive agreement to acquire Ciitizen Corporation from group of investors for approximately $350 million.

Chief Medical Officer recently sold US$540k worth of stock

Exact Sciences Approaches Invitae

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.29 loss in 2Q 2020)

Director Jason Myers has left the company

Chief Financial Officer Shelly Guyer has left the company

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen